Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 299

1.

Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.

Kuti JL, Ghazi IM, Quintiliani R Jr, Shore E, Nicolau DP.

Int J Antimicrob Agents. 2016 Sep;48(3):342-3. doi: 10.1016/j.ijantimicag.2016.06.005. Epub 2016 Jul 8. No abstract available.

PMID:
27451086
2.

Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin.

Housman ST, Thabit AK, Kuti JL, Quintiliani R, Nicolau DP.

Infect Control Hosp Epidemiol. 2016 Feb;37(2):215-8. doi: 10.1017/ice.2015.270. Epub 2015 Nov 23.

PMID:
26592763
3.

Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit.

Bhalodi AA, Keel RA, Quintiliani R, Lodise TP, Nicolau DP, Kuti JL.

Ann Pharmacother. 2013 May;47(5):617-27. doi: 10.1345/aph.1R789. Epub 2013 Apr 12.

PMID:
23585647
4.

Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers.

Wiskirchen DE, Housman ST, Quintiliani R, Nicolau DP, Kuti JL.

Pharmacotherapy. 2013 Mar;33(3):266-74. doi: 10.1002/phar.1197. Epub 2013 Feb 11.

PMID:
23400916
5.

Pneumonia due to Pseudomonas aeruginosa: part II: antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy.

Sun HY, Fujitani S, Quintiliani R, Yu VL.

Chest. 2011 May;139(5):1172-1185. doi: 10.1378/chest.10-0167. Review.

PMID:
21540216
6.

Infusion phlebitis: relative incidence associated with cefuroxime administered by intermittent and continuous infusion.

Owens CA, Ambrose PG, Quintiliani R, Nightingale CH, Nicolau DP.

Clin Drug Investig. 1998;15(6):531-5. No abstract available.

PMID:
18370511
7.

Pharmacokinetics/Pharmacodynamics for critical care clinicians.

Quintiliani R Sr, Quintiliani R Jr.

Crit Care Clin. 2008 Apr;24(2):335-48, xi. doi: 10.1016/j.ccc.2007.12.008. Review.

PMID:
18361949
8.

Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem.

Nicasio AM, Quintiliani R Jr, DeRyke CA, Kuti JL, Nicolau DP.

Ann Pharmacother. 2007 Jun;41(6):1077-81. Epub 2007 May 1.

PMID:
17472997
9.

Acute exacerbation of chronic bronchitis: a primary care consensus guideline.

Brunton S, Carmichael BP, Colgan R, Feeney AS, Fendrick AM, Quintiliani R, Scott G.

Am J Manag Care. 2004 Oct;10(10):689-96. Review.

10.

Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase.

Li C, Nicolau DP, Lister PD, Quintiliani R, Nightingale CH.

J Antimicrob Chemother. 2004 Feb;53(2):297-304. Epub 2004 Jan 16.

PMID:
14729755
11.

The CroRS two-component regulatory system is required for intrinsic beta-lactam resistance in Enterococcus faecalis.

Comenge Y, Quintiliani R Jr, Li L, Dubost L, Brouard JP, Hugonnet JE, Arthur M.

J Bacteriol. 2003 Dec;185(24):7184-92.

12.

Inhalational anthrax and bioterrorism.

Quintiliani R Jr, Quintiliani R.

Curr Opin Pulm Med. 2003 May;9(3):221-6. Review.

PMID:
12682568
13.

Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oral.

Kuti JL, Le TN, Nightingale CH, Nicolau DP, Quintiliani R.

Am J Health Syst Pharm. 2002 Nov 15;59(22):2209-15.

PMID:
12455304
14.

Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.

Kuti JL, Nightingale CH, Quintiliani R, Nicolau D.

Diagn Microbiol Infect Dis. 2002 Sep;44(1):51-7.

PMID:
12376031
15.

Minimal interaction between gatifloxacin and oxycodone.

Grant EM, Nicolau DR, Nightingale C, Quintiliani R.

J Clin Pharmacol. 2002 Aug;42(8):928-32.

PMID:
12162476
16.

Fatal case of inhalational anthrax mimicking intra-abdominal sepsis.

Quintiliani R Jr, Quintiliani R.

Conn Med. 2002 May;66(5):261-7.

PMID:
12071107
17.

Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.

Kim MK, Capitano B, Mattoes HM, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP.

Pharmacotherapy. 2002 May;22(5):569-77.

PMID:
12013355
18.

Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H.

Mattoes HM, Capitano B, Kim MK, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP.

Chemotherapy. 2002 May;48(2):59-63.

PMID:
12011536
19.

Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.

Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R.

Pharmacotherapy. 2002 Apr;22(4):471-83.

PMID:
11939682
20.

Extended-spectrum beta-lactamases (ESBL).

Dandekar PK, Quintiliani R, Nightingale CH, Nicolau DP.

Conn Med. 2002 Jan;66(1):13-5. Review. No abstract available.

PMID:
11852734
21.
22.

Antibacterials for the prophylaxis and treatment of bacterial endocarditis in children.

Capitano B, Quintiliani R, Nightingale CH, Nicolau DP.

Paediatr Drugs. 2001;3(10):703-18. Review.

PMID:
11706922
23.

Moxifloxacin does increase the corrected QT interval.

White CM, Grant EM, Quintiliani R.

Clin Infect Dis. 2001 Oct 15;33(8):1441-4. No abstract available.

PMID:
11565091
24.

Guidelines for treatment of community-acquired pneumonia.

Kim MK, Nightingale C, Quintiliani R.

Conn Med. 2001 Aug;65(8):473-5. No abstract available.

PMID:
11550446
25.

Hormonal adaptation to real and simulated microgravity.

Strollo F, Strollo G, More M, Bollanti L, Ciarmatori A, Longo E, Quintiliani R, Mambro A, Mangrossa N, Ferretti C.

J Gravit Physiol. 1998 Jul;5(1):P89-92. Review.

PMID:
11542377
26.

Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam.

Kim MK, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP.

J Antimicrob Chemother. 2001 Aug;48(2):259-67.

PMID:
11481298
27.

Introduction. Designing a transition therapy program.

Quintiliani R.

Pharmacotherapy. 2001 Jul;21(7 Pt 2):77S-78S. No abstract available.

PMID:
11446521
28.

Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia.

Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH.

Int J Antimicrob Agents. 2001 Jun;17(6):497-504.

PMID:
11397621
29.

Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens.

Owens RC Jr, Tessier P, Nightingale CH, Ambrose PG, Quintiliani R, Nicolau DP.

Int J Antimicrob Agents. 2001 Jun;17(6):483-9.

PMID:
11397619
30.

Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia.

McNabb JJ, Nightingale CH, Quintiliani R, Nicolau DP.

Pharmacotherapy. 2001 May;21(5):549-55.

PMID:
11349744
31.

Circulating tumor necrosis factor-alpha production during the progression of rat endotoxic sepsis.

Xuan D, Nicolau DP, Nightingale CH, Quintiliani R.

Chemotherapy. 2001 May-Jun;47(3):194-202.

PMID:
11306788
32.

Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients.

Bui KQ, Ambrose PG, Nicolau DP, Lapin CD, Nightingale CH, Quintiliani R.

Chemotherapy. 2001 May-Jun;47(3):153-6.

PMID:
11306783
33.

Drug therapy for methicillin-resistant Staphylococcus aureus.

Quintiliani R, Kuti J.

Conn Med. 2001 Jan;65(1):23-5. Review. No abstract available.

PMID:
11227621
34.

Transitional (intravenous to oral) antibiotic therapy.

Quintiliani R, Grant E, Quintiliani R Jr.

J Med Liban. 2000 Jul-Aug;48(4):233-40.

PMID:
11214195
35.

Optimizing clinical outcomes by the use of pharmokinetic and pharmacodynamic principles.

Quintiliani R.

J Med Liban. 2000 Jul-Aug;48(4):182-5. Review.

PMID:
11214187
36.

Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.

Grant EM, Zhong M, Fitzgerald JF, Nicolau DP, Nightingale C, Quintiliani R.

J Clin Pharmacol. 2001 Feb;41(2):206-9.

PMID:
11210403
37.

Comparison of azithromycin leukocyte disposition in healthy volunteers and volunteers with AIDS.

McNabb J, Owens RC, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP.

Int J Antimicrob Agents. 2000 Sep;16(1):37-43.

PMID:
11185411
38.

Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.

Xuan D, Zhong M, Mattoes H, Bui KQ, McNabb J, Nicolau DP, Quintiliani R, Nightingale CH.

Antimicrob Agents Chemother. 2001 Mar;45(3):794-9.

39.

Regulation of VanA- and VanB-type glycopeptide resistance in enterococci.

Arthur M, Quintiliani R Jr.

Antimicrob Agents Chemother. 2001 Feb;45(2):375-81. Review. No abstract available.

40.
41.

Limitations of single point pharmacodynamic analysis.

Ambrose PG, Quintiliani R.

Pediatr Infect Dis J. 2000 Aug;19(8):769. No abstract available.

PMID:
10959755
42.

Cost-effectiveness in the use of antibiotics.

McNabb J, Quintiliani R, Nicolau DP, Grant E, Nightingale CH.

Curr Clin Top Infect Dis. 2000;20:24-42. Review. No abstract available.

PMID:
10943517
43.

Comparison of vancomycin pharmacodynamics (1 g every 12 or 24 h) against methicillin-resistant staphylococci.

Lacy MK, Tessier PR, Nicolau DP, Nightingale CH, Quintiliani R.

Int J Antimicrob Agents. 2000 Jun;15(1):25-30.

PMID:
10856673
44.

Stability of meropenem in a portable infusion device in a cold pouch.

Grant EM, Zhong MK, Ambrose PG, Nicolau DP, Nightingale CH, Quintiliani R.

Am J Health Syst Pharm. 2000 May 15;57(10):992-5. No abstract available.

PMID:
10832500
45.

Quinupristin/dalfopristin: a treatment option for vancomycin-resistant Enterococci.

Kim MK, Nicolau DP, Nightingale CH, Quintiliani R.

Conn Med. 2000 Apr;64(4):209-12. No abstract available.

PMID:
10812767
46.

Pharmacodynamics and pharmacokinetics of levofloxacin.

Nightingale CH, Grant EM, Quintiliani R.

Chemotherapy. 2000;46 Suppl 1:6-14. Review.

PMID:
10810208
47.

In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.

Bui KQ, Banevicius MA, Nightingale CH, Quintiliani R, Nicolau DP.

J Antimicrob Chemother. 2000 Jan;45(1):57-62.

PMID:
10629013
48.

Protective effect of trovafloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in a murine sepsis model.

Lacy MK, Nicolau DP, Banevicius MA, Nightingale CH, Quintiliani R.

J Antimicrob Chemother. 1999 Oct;44(4):477-81.

PMID:
10588309
49.

Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model.

Nicolau DP, Banevicius MA, Nightingale CH, Quintiliani R.

Antimicrob Agents Chemother. 1999 Dec;43(12):3033-5.

50.

Oral bioavailability and pharmacokinetics of trovafloxacin in patients with AIDS.

Lacy MK, Nicolau DP, Nightingale CH, Geffken A, Teng R, Vincent J, Quintiliani R.

Antimicrob Agents Chemother. 1999 Dec;43(12):3005-7.

Supplemental Content

Loading ...
Support Center